SCHEMBL5337374

SCHEMBL5337374

CCCCC1CCN(CCCC(=O)c2sc3ccc(F)cc3c2C)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.53
CHRM1 P11229 4/20 0.53
CHRM5 P08912 2/20 0.53
CHRM3 P20309 2/20 0.53
CHRM2 P08172 2/20 0.53
HTR1A P08908 2/20 0.53
ADRA2A P08913 2/20 0.53
ADRA1A P35348 2/20 0.53
CHRM4 P08173 1/20 0.53
ADRA2B P18089 1/20 0.53
DRD4 P21917 1/20 0.53
ADRA1D P25100 1/20 0.53
HRH1 P35367 1/20 0.53
ADRA1B P35368 1/20 0.53
MEN1 O00255 1/20 0.43
DRD1 P21728 1/20 0.43
OPRM1 P35372 1/20 0.43
DRD3 P35462 1/20 0.43
KMT2A Q03164 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336905 0.81 CHRM1 (0.46) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL4494357 0.79 CHRM1 (0.72) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL5332206 0.78 CHRM1 (0.59) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL27559651 0.75 CHRM1 (0.60) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL7010010 0.73 CHRM1 (0.35) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL4654218 0.72 HTR7 (0.48) HTR7
SCHEMBL4500536 0.72 CHRM1 (0.67) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL7013487 0.71 DRD2 (0.49) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL5335803 0.71 DRD2 (0.61) DRD2CHRM1CHRM5CHRM3CHRM2
SCHEMBL4510024 0.71 DRD2 (0.77) DRD2CHRM1CHRM5CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US claimed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US claimed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US claimed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US claimed
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US disclosed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP disclosed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US disclosed
EP-1278741-B1 MUSCARINIC AGONISTS ACADIA PHARM INC (US) 2005-03-02 EP disclosed
US-6627645-B2 Cholinergic agents ACADIA PHARMACEUTICALS, INC. 2003-09-30 US disclosed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037886-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 DRD2 476/4885CHRM1 2/4885CHRM5 5/4885
US-20070155795-A1 MUSCARINIC AGONISTS CHRM2, CHRM1, CHRM4 DRD2 476/4885CHRM1 2/4885CHRM5 5/4885
US-20050113357-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 DRD2 476/4885CHRM1 2/4885CHRM5 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.